Mission Pharmacal Company and EffRx Bring New Osteoporosis Medication to the United States and Canada
4/18/2012 9:47:56 AM
More...
|
FDA Approves EffRx's BINOSTO®, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution
3/14/2012 9:34:24 AM
More...
|
EffRx Announces Issuance of US Patent Providing Further Protection to EX101, Effervescent Alendronate Weekly Dosing Form
7/11/2011 11:06:09 AM
More...
|
First EffRx NDA Accepted for Filing by the FDA
5/11/2011 8:23:22 AM
More...
|
EffRx Pharmaceuticals SA Announces Move from United States to Switzerland and Appointment of New Management and Board Members
1/11/2011 9:35:53 AM
More...
|
EffRx and Nycomed Announces First European Filing for Marketing Approval of Osteoporosis Drug Targeting Increased Convenience for Patients
9/21/2010 10:34:17 AM
More...
|
EffRx Signs Licensing Deal with Nycomed for Its Novel Effervescent Osteoporosis Drug EX101; EffRx Will Receive Payments up to $59 Million
1/14/2009 6:50:53 AM
More...
|